ArticleThe Lancet. Respiratory medicine2023

Cardiac and vascular serious adverse events following tixagevimab-cilgavimab - Author's reply.

Sheetal Maselkar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.